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Sustained release theophylline tablets and capsules were prepared with dika fat, a solid vegetable oil 
extracted from the kernels of Irvingia gabonesis var gabonesis and var excelsia. Anhydrous theophylline 
was incorporated into dika fat by the fusion method. The in vitro release of the theophylline was 
monitored by the so-called half change dissolution method in stimulated gastric juice USP without 
pepsin and in stimulated intestinal juice without pancreatin, respectively. The USP XX paddle method 
was used. A level of sustained release was achieved over a 6-h period in both the tabletted and 
encapsulated dosage forms. The theophylline formulations containing dika fat, prepared in this study, 
exhibited dissolution profiles similar to those of Theo 24, Theodur and Respid, some commercial 
sustained release theophylline formulations. 
 




Dika fat is a solid edible vegetable oil extracted from 
the kernels of Irvingia gabonesis var gabonesis and 
var excelsia. It is a dry, free flowing non-caking 
powder, low in ash content and with practically no 
trace of heavy metals. Dika fat shows superior 
inertness and excellent storage stability (Onyechi, 
1987). This fat has been evaluated as a tablet 
lubricant in basic lactose granulation in which it is 
most effective when added in the dry state in the 
last blending operation before compression (Udeala 
et al., 1980). 
 Oral administration of drugs using 
controlled release formulations is a popular concept 
which has attracted the attention of formulation 
pharmacists for over five decades. This is because 
of the advantages such formulations have over their 
conventional counterparts. The advantages include: 
reduction of dosage frequency, constant 
pharmacodynamic response, patient compliance 
and reduction of side effects of active ingredients. 
 Most commercially available sustained 
release products exploit one of two simple 
mechanisms. These are, a reservoir limited by a 
diffusional barrier (Rao et al, 1988) and a matrix in 
which drug is embedded (Conti et al, 2007). In 
matrix devices, the drug is incorporated into a non-
disintegrating inert matrix. Drug release in such 
devices is defined by a pore structure created by 
leaching the soluble drug, with, if necessary, soluble 
carriers. Theoretically the release rate is 
proportional to the square root of time (Korsmeyer 
et al., 1983). Other matrix devices simply erode in 
the gastrointestinal tract, drug release rate declining 
with surface area (Karasulu et al., 2000). 
 The purpose of this study was to evaluate 
the potential of Dika fat as a sustained release 
excipient. Theophylline was dispersed in a matrix 
system containing dika fat by the fusion method. 
The formulation mixture was either encapsulated or 
tabletted and evaluated for theophylline release in  
 
vitro. Theophylline was chosen as a model drug for 
this study because it possesses some of the 
properties of drugs best suited for sustained release 
formulations. These properties include short half-
life, small dose, and uniform absorption in the 
gastro-intestinal tract and use in the treatment of 
chronic conditions (BNF, 2002-2003). Also, 
theophylline has been subject of publications on 
sustained release (Ofoefule and Chukwu, 1998; 
Semde et al., 2000; Saha et al., 2001; Jianhong et 
al., 2005). 
 
Materials and Methods 
 
Materials: Dika fat was obtained from Irvingia 
gabonesis var gabonesis and var excelsia by 
soxhlet extraction as previously described (Onyechi, 
1987). The fat was further purified, bleached and 
deodorized (Onyechi, 1987). 
 The following chemicals were used as 
purchased from the manufacturers: lactose USP, 
theophylline, monobasic potassium phosphate 
(Merck, USA), sodium hydroxide, sodium chloride, 
hydrochloric acid (M&B Chemicals), magnesium 
stearate (BDH chemicals), Fast Flo Lactose 
(Foremost Diaries, USA) Slow-Bid (William Rorer 
Inc., USA) Theo 24 (Searle and Co., USA) and 
Theodur (Key Pharm., USA). RESPID (Boehringer 
Ingelheim, USA) tablets were also used. 
 
Differential scanning calorimetry (DSC): Thermal 
analyses were performed on dika fat, theophylline 
and 1:1 (w/w) physical mixture of dika fat and 
theophylline respectively. Thermal curves were 
obtained using a Perkin-Elmer DSC-4 Differential 
Scanning Calorimeter (Perkin-Elmer Corp., 
Norwalk, CT, USA) equipped with a Bascom Turner 
Recorder and Data Acquisition system (Bascom 
Turner Instruments, MT, USA). After being firmly 
powdered, 2-8 mg samples of test substances were 
weighed out and encapsulated in an aluminum pan 
with crimp-on lids. Thermograms were obtained at a 
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constant heating range setting of 20 mcal per 
minute, in an atmosphere of nitrogen and recorded 
at a constant chart speed of one inch per minute. 
Theophylline and a 1:1 mixture of the drug and dika 
fat were heated over the temperature range 20 to 
2200C. 
 
Preparation of theophylline granules: A 500g 
sample of granules was a formulated to contain 60, 
20 and 20% w/w dika fat, theophylline and lactose 
respectively. Theophylline and lactose were added 
with stirring to the molten dika fat. The stirring was 
continued until cold when the melt solidified, 
thereby ensuring even distribution of the drug. The 
solid mass was ground and sieved through 
0.595mm aperture screen. The granules were air 
dried overnight under room temperature of 28±10C. 
 
Preparation of theophylline capsules: The 
granules prepared as described previously were 
manually filled into No 00 hard gelatin capsules. 
Each capsule contained theophylline granules 
equivalent to 150mg of the pure drug. 
 
Compression of theophylline tablets: A 1:1 (w/w) 
mixture of Fast flo lactose and dibasic calcium 
phosphate was mixed with the theophylline 
granules prepared as previously described. This 
ensured the compressibility of the granules. 
 A batch of 500g powder mix containing 
theophylline granules, Fast flo lactose and dibasic 
calcium phosphate in 1:1:1 ratio was prepared. This 
was blended for 15 min in a Rotomixer (Foster 
Equipment Co. Ltd., Leicester, England). A 1% w/w 
magnesium stearate, the lubricant was then added 
and the blending was continued for another 5 min. 
The tablets were compressed in a KORSCH single 
punch tablet press (Type EKO, No.9228, Erweka 
Apparatebau GMBH, W. Germany) fitted with 
9.5mm flat faced and bevelled punches. The tablet 
target weight was 600mg and the hardness was 
fixed at 5kg. 
 
Evaluation of tablet hardness: The tablet 
hardness was determined on an Erweka  hardness 
tester (Type TBH 28, No. 50675, Erweka 
Apparatebau GMBH, W. Germany) 24 h after the 
tablet had been made. The average of ten such 
determinations was calculated. 
 
Dissolution studies: Theophylline release rates 
from the dosage forms were monitored over a 6-h 
period using an Erweka dissolution apparatus 
(Erweka Aparatebau, Type DTD, No 50288, and W. 
Germany). A 900ml volume of either simulated 
gastric juice (SGJ) USP XX without pepsin or 
stimulated intestinal juice (SIJ) USP XX without 
pancreatin respectively, maintained at 370C was 
used as the dissolution medium. The spindle of the 
dissolution apparatus was fixed to rotate at 50 rpm 
and the capsules were prevented from floating by 
the aid of a stainless steel helical spring. 
 The release rate of theophylline was 
monitored by the so-called half change dissolution 
method. A 500ml volume of SGJ USP without 
pepsin was used for the first hour, after which 
250ml of this was removed and replaced by SIJ 
USP without pancreatic, maintained at the same 
temperature as the dissolution medium. The 
dissolution was continued for another hour after 
which 250ml of medium was removed and replaced. 
This procedure was repeated for the 6-h duration of 
the testing. 
 Analysis for the drug content of samples of 
the dissolution medium was performed using an 
SP8-400 UV/VIS spectrophotometer (Pye Unicam 
Ltd., Cambridge England). The absorbance of 
theophylline was measured at 270nm. 
 Percent drug dissolved was determined 
from the Beers law plot previously constructed 
using SGJ USP without pepsin and SIJ, USP 
without pancreatin, as media, respectively. The data 
was plotted as cumulative percent drug dissolved 
against time and each datum point represents the 
average of five dissolution test runs. 
 
Results and Discussion 
 
DSC experiments were undertaken to ascertain the 
compatibility of theophylline with dika fat. Fig. 1 
shows the thermal curves for theophylline, dika fat 
and a mixture of the drug with dika fat. The 
transition temperature range for the melting 
endotherm of pure theophylline is from 270 - 2800C. 
The average maximum peak of transition is at 
2740C. This transition peak corresponds to the 
melting of theophylline. The thermal curve for the 
mixture of dika fat and theophylline (Fig. 1 c) 
combined the features characteristic of the curves 
for the dika fat (Fig. 1a) and theophylline (Fig. 1b). 
McDaid et al. (2003) have stated that incompatibility 
is highly improbable if the thermal curve of a 
mixture is a simple superposition of those of the 









theophylline is therefore highly improbable. The 
release rates of theophylline from test tablets 
containing dika fat were determined and compared 
with those of commercially available dosage forms. 
The dissolution data is depicted in Fig. 2. Clearly 
there is prolonged release of theophylline from all 
the tablet formulations. Theoretically, sustained 
release products need only produce satisfactory 
therapeutic response with reduced frequency of 
administration.  
Fig. 1: DSC thermograms for a) dika fat; b) 
theophylline and c) 1:1 physical mixture of 
dika fat and theophylline 
Temperature oC 































































Practically the release of drugs from the products 
should be at controlled and predictable rate. All the 
formulations appear to release theophylline at 
predictable rates. However, only the test tablets 
formulated with dika fat or THEODUR released the 
drug at near constant rates. Drug release rate in 
matrix devices may be proportional to the square 
root of time. In matrix devices and diffusion 
systems, where membrane permeation is the 
dominant mode of controlling drug release, rate of 
release is known to be proportional to the square 
root of time (Higuchi, 1963). In the case where 
matrix diffusion is the predominant mode of 
controlling drug release the rate may be constant 
(Higuchi, 1963). Fig. 3 shows the square root of 
time plot for drug release from tablets evaluated in 
this study. Theophylline release from the tablets, at 
successive time intervals, is near constant, 
indicating that these systems are diffusion 
controlled. The non-linearity at the onset and 
towards the end of dissolution test may be due to 
surface drug and finite changes in the surface area 
of the tablet. The latter should result in decreased 
theophylline release. Other factors which modify 
drug release in matrix systems are solubility of the 
drug (Brossard et al., 1983; Saha et al., 2001; 
Jambhekar et al., 1987) and formulation additives 
(Khan and Zhu, 1999; Rohera and Parikh, 2002; 
Tang et al., 2000). 




























Fig. 2: Dissolution profiles of SR 
theophylline tablets evaluated





























Fig. 3: The square root of time plot 
for the dissolution of SR
theophylline tablets by the half





























 The dissolution profiles of theophylline 
capsules are shown in Fig. 4. The corresponding 
plots of square root of time versus percent released 
from the same dosage forms are shown in Fig.5. 
Theophylline release was fastest in ELIXOPHYLLIN 
capsules. This was to be expected in view of the 
observed faster disintegration of the dosage form 
when compared with other encapsulated products. 
As with the tablet dosage forms, theophylline 
release were also clearly prolonged in the capsule 
dosage forms. The release rates though not 
constant appear to be predictable especially in 
SLOW-BID, THEO-24, THEOBID and the capsules 
formulated with dika fat. 
 Some drugs are known to exhibit pH 
specifity in dissolution studies either as a result of 
their chemistry or formulation. Drug regulatory 
requirements therefore recommend the testing of 
sustained release products at pH levels and in 
solutions similar to those of gastric and intestinal 
fluids. The effect of pH of the dissolution medium on 
the dissolution of theophylline from the products 
was evaluated. The data obtained are shown in 
Figs 6 and 7 which are for tablets and capsules 
formulated with dika fat respectively. It can be seen 
from both figures that theophylline release was 
greater in stimulated intestinal juice than in 
stimulated gastric juice. Theophylline dissolution 
from the dosage form may be dependant on 
whether the drug in the dosage form is the acid 
which is less soluble than the salt. The relative 
lower solubility of theophylline at low pH should 
explain the higher dissolution of the drug in the 
alkaline SIJ in contrast to the lower dissolution 
obtained in the acidic SGJ. 
 
Conclusion: It has been shown that dika fat can be 
used in the formulation of sustained release 
theophylline dosage forms by simple fusion method. 
The product may be formulated either as tablets or 
capsules. However, such formulations should show 
pH specificity in drug release. The in vivo evaluation 
of theophylline released, in vitro-in vivo correlation 
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Fig. 7: Dissolution profiles of SR

























SIJ USP without pancreatin
SGJ without pepsin
Half change method
Fig. 6: Dissolution profiles of SR































SIJ USP without pancreatin
SGJ without pepsin
Half change method
Fig. 5: The square root of time plot 
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